Targets › ERVCC
1 program from 1 company in 2 trials: 2 Phase 2; Infectious disease; next expected readout Nov 2027.
Open in Phaseline: the race on ERVCC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Altesa Biosciences | Vapendavir VP1 capsid protein inhibitor | ERVCC | Phase 2 | Rhinovirus Infection | Nov 2027 |
Rhinovirus Infection (2)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.